1323 results about "Avian virus" patented technology

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

The present invention provides a vaccine, method of use, and kit employing genetically isolated and stabilized, live attenuated bacterial strains including Salmonella that express one or more avian influenza antigens for use in live vaccine compositions that can be orally administered to an individual to protect against avian influenza. Genetic stabilization may be achieved through deletion of IS200 elements and bacteria phage and prophage elements. The bacterial strains may be genetically isolated from external phage infection by constitutive expression of a P22 phage repressor. Nucleic acid sequences encoding antigenic hemagglutinin and neuraminidase avian influenza proteins, having at least one modified codon for optimum expression when transferred into a prokaryotic microorganism for improved immunogenicity

This invention relates to a monoclonal antibody capable of combining with H5 subtype avian influenza virus HA protein specifically, the hybridoma cell line secreting said antibody and a preparing method. The invention also relates to a serial test kit for testing H5 subtype avian influenza virus by the antibody and a bit of said antibody in the test sample of the virus and its usage in treatment.

The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against avian influenza.

The invention relates to a composition for widely treating viral diseases. The composition contains the following raw materials, or extracts of the following raw materials, or derivatives of the extracts of the following raw materials in chemically-acceptable forms, wherein the raw materials include processed products prepared from the raw materials. The constituents of the composition are as follows: 100 parts of Baikal skullcap root, 50-150 parts of radix bupleuri and 50-150 parts of kudzu root; and according to specific circumstances, one or more selected from (but not limited to) the following raw materials can be added on this basis: radix isatidis, honeysuckle flower, Fructus Forsythiae, rhubarb, phellodendron bark, rhizoma anemarrhenae, Cyrtomium fortunei, gardenia, coptis, rhizoma cyperi, fritillaria, balloonflower and licorice root. The composition provided by the invention can be prepared into powder, liquid, paste, granules, capsules or other pharmaceutically-acceptable physical forms. The composition provided by the invention is used for preventing and treating avian influenza, epidemic hemorrhagic fever, epidemic parotitis, nameless hyperpyrexia, Newcastle diseases, swine fever, blue-ear diseases and other multiple human and animal viral diseases characterized by hemorrhage or body temperature rise, and reducing the degree of pathological damage to the body.

The invention discloses a serum-free medium for Madin-Darby canine kidney (MDCK) cell full suspension culture. The serum-free medium for MDCK cell full suspension culture comprises an amino acid part, a vitamin part, an inorganic salt part and other additive parts. The serum-free medium has the beneficial effects that the serum-free medium for MDCK cell full suspension culture, provided by the invention, is high in cell culture density and clear in composition and does not contain animal serum, a downstream product is purified, the product quality is improved, and the serum-free medium is convenient to prepare and use and suitable for large-scale production of influenza vaccines and avian influenza vaccines.

A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.

Described in this application are attenuated strains of avian influenza virus containing temperature sensitive mutations in addition to a genetic tag in the PB1 gene. The attenuated viruses are useful as avian and mammalian vaccine for protective immunity against homologous and heterologous lethal challenges with influenza virus. A genetically modified avian influenza virus backbone is described which can be used as a master donor strain for the generation of live attenuated vaccines for epidemic and pandemic influenza.

The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.

The invention provides a method for detecting fowl influenza virus and parting primer system and augmenting fowl influenza virus RNA asymmetrically. The invention designs and screens 25 pairs multiple asymmetrical RT-PCR primers, a pair general primer, 52 specific probes and 3 quality control probes according to the report fowl influenza virus total hypotype genome sequence in Genebank, wherein every pair in 25 pairs multiple asymmetrical RT-PCR primers is fit for a hypotype of fowl influenza virus, the primer system comprising 25 pairs multiple asymmetrical RT-PCR primers and a pair general primer can be used for detecting and parting fowl influenza virus, the primer system builds the method of asymmetrically augmenting fowl influenza virus RNA and detecting and parting fowl influenza virus. The invention provides strong specificity, high sensibility, which also proceeds the first step application.

The invention relates to a method and a detection kit used for detecting a virus. The method comprises steps that: an antibody of the glycoprotein of a target virus adventitia is coupled with magnetic nano/micro-spheres, such that immunized magnetic nano/micro-spheres are obtained; the immunized magnetic nano/micro-spheres are used for catching the target virus in the sample, such that a magnetic sphere virus composition is obtained; the antibody of the glycoprotein of the adventitia of the biotinylated virus is incubated with the magnetic sphere virus composition; the obtained material is incubated with streptavidin-coupled quantum dots, such that a magnetic sphere-virus-quantum dot composition is obtained; and the virus is detected through the detection upon fluorescence signals of the magnetic sphere-virus-quantum dot composition. With the method, specific recognition, preconcentration, separation, and high-sensitivity detection of H9N2 subtype avian influenza active virus can be realized. The invention also provides a detection kit employed by the method. The kit and the method provided by the invention are characterized by simple operation, high specificity, high sensitivity, and the like. The whole detection process can be finished in one hour.

Antimicrobial compositions having a rapid and persistent antiviral effectiveness against influenza viruses, including avian flu viruses, are disclosed. The antimicrobial compositions contain (a) a disinfecting alcohol, (b) an organic acid, and (c) water, wherein the composition has a pH of about 5 or less and the nonvolatile components of the composition are capable of forming a barrier film or layer on a treated surface.

The present invention relates to an artificially synthesized gene optiHA containing codons for chicken partial tropism. Its reading frame contains 1707 bp nucleotides and encodes a total of 568 amino acids. The gene is compatible with H5 subtype highly pathogenic avian influenza virus A/ Goose/GuangDong/1/96(H5N1)[GD/1/96(H5N1)]hemagglutinin (HA) gene has a nucleotide homology rate of 70%, an amino acid homology rate of 100%, and encodes the H5 subtype Hemagglutinin (HA) protein of avian influenza virus GD/1/96 (H5N1). The invention also relates to the application of the gene as an immunogenic gene of H5 subtype influenza DNA vaccine and other genetic engineering vaccines.

A method and composition for preventing and treating Avian Influenza in Humans utilizes an effective quantity of polyphenolic(s) and/or its derivatives in combination with a carrier. The anti-avian influenza ingredient having a composition selected from the group consisting of theaflavin, theaflavin-3,3′-digallate, theaflavin-3-monogallate, theaflavin-3 gallate, theaflavin-3′-gallate, thearubigin, gallic acid, tannic acid, (−)-epigallocatechin gallate (EGCG), (−) epigalloatechin (EGC), (+)-epicatechin (EC), (−)-gallocatechin gallate (GCG), and catechin.

The invention aims at providing an I-colony fowl adenovirus 4 strain, which is preserved with preservation number of CCTCC No. V201541. The I-colony fowl adenovirus 4 YBAV-4 strain disclosed by the invention is excellent in specificity and immunogenicity; a specific precipitation line does not appear in specific positive serum chicken SPF chicken serum such as infected cell sap and egg drop syndrome resisting virus, chicken infectious bursal disease virus, Newcastle disease virus, chicken infectious laryngotracheitis virus, chicken Marek's disease virus, avian influenza and the like, while an obvious specific precipitation line appears in I-colony fowl adenovirus 4 specific serum. The strain disclosed by the invention, as a vaccine strain which is good in manufacturing effect, is capable of preventing chicken hydropericardium syndrome, and the strain is applicable to identification of virus serotype and investigation on epidemiology.

An immunoadjuvant used to prepare the antiviral vaccine or medicine for increasing the immune activity of the antigens for HBV, HCV, SARS coronavirus, fowl influenza virus, etc is a kind of human or animal's novel heat shock proteins gp96, hsp108 and hsp70.

The invention discloses a preparation method of an avian influenza virus suitable for growing in a serum-free full-suspended cultured MDCK cell line and the avian influenza virus obtained through the method. The preparation method comprises the following steps of 1 preparation of the MDCK cells to be inoculated; 2 virus seed preparation, wherein a chick embryo source avian influenza virus is prepared; 3 F1 generation virus domestication; 4 F2 generation virus domestication, wherein a supernatant sample retained at the time point when the blood clotting titer of the avian influenza virus obtained in the F1 generation is highest is taken, and the step 3 is repeated; 5 F3 generation virus domestication, wherein the F3 generation virus culturing temperature is 35 DEG C; 6 F4 generation-F10 generation virus domestication, wherein the step 5 is repeated, and the domesticated avian influenza virus is obtained. According to the preparation method, through a domestication method, the avian influenza virus is directly domesticated to completely adapt to be efficiently reproduced on the serum-free full-suspended cultured MDCK cells from the mode of being cultured by a chick embryo, the domestication efficiency is high, the avian influenza virus can be efficiently infected and copied in the MDCK cells, and the virus characteristic is stable.

The present invention relates to adenovirus-based vaccines against avian influenza viruses with pandemic potential. The present invention provides replication-defective adenoviral vectors, each having a nucleic acid encoding an influenza A polypeptide. When introduced into a subject, the expressed influenza A polypeptide induces the production of antibodies that bind to influenza. The present invention also provides methods for inducing an immune response in a subject. Subjects are administered a replication-defective adenoviral vector, wherein the vector has a nucleic acid encoding an influenza A polypeptide. When the vector is expressed in the subject, the influenza A polypeptide induces the subject to produce antibodies to influenza.